

Ondansetron for the treatment of irritable bowel syndrome (IBS) with diarrhoea (IBS-D): identifying the responder

Submission date 31/03/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 31/03/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 26/07/2016	Condition category Digestive System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Ms Klara Garsed

Contact details
Queens Medical Centre
Derby Road
Nottingham
United Kingdom
NG7 2UH

Additional identifiers

Clinical Trials Information System (CTIS)
2008-000623-25

ClinicalTrials.gov (NCT)
NCT00745004

Protocol serial number
6965

Study information

Scientific Title

A randomised interventional multicentre trial of ondansetron versus placebo in the treatment of patients with irritable bowel syndrome (IBS) with diarrhoea (IBS-D)

Acronym

Ondansetron for IBS-D

Study objectives

Irritable bowel syndrome (IBS) is a common problem, with often distressing symptoms that can result in a reduced quality of life. This is a two centre randomised double blind placebo controlled crossover trial of Ondansetron in IBS-D. The aim is to identify clinical, laboratory, and magnetic resonance imaging (MRI) scan features that will predict response in clinical practice. The primary outcome measure is a change in stool average stool consistency in the last 2 weeks of treatment of Ondansetron versus placebo.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Nottingham Research Ethics Committee 2, 10/11/2008, ref: 08/H0408/134

Study design

Randomised interventional multicentre treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Primary Care Research Network for England; Subtopic: Not Assigned; Disease: All Diseases

Interventions

Double blind placebo, this is a randomised double blind placebo controlled trial

1. A 1 week screening period where the subject completes a daily stool diary
2. Treatment period 1 (5 weeks) where the subject receives either placebo or 4 mg of ondansetron titrated to a dose of min 4 mg every other day, max 8 mg three times a day
3. A 2 week washout
4. A second treatment period (5 weeks) where the subject receives either placebo or active therapy with ondansetron depending on which therapy was administered in treatment

Study Entry: Single Randomisation only

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Ondansetron

Primary outcome(s)

Difference in average stool consistency in the last 2 weeks of treatment of Ondansetron versus placebo

Key secondary outcome(s)

Measured against the primary endpoint in the final 2 weeks of each treatment period:

1. Proportion of patients preferring ondansetron versus placebo
2. Proportion wanting to continue with ondansetron

Completion date

31/01/2011

Eligibility

Key inclusion criteria

1. Patients with IBS-D meeting the Rome III criteria
2. Patients able to give informed consent
3. Female patients of child bearing potential are willing to use at least one highly effective contraceptive method
4. Aged 18 years and over, either sex

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Women who are pregnant or breast feeding
2. Patients unable to stop anti-diarrhoeal drugs
3. Patients currently in, or have been in another clinical trial in the previous 3 months

Date of first enrolment

01/01/2009

Date of final enrolment

31/01/2011

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Queens Medical Centre

Nottingham

United Kingdom

NG7 2UH

Sponsor information

Organisation

University of Nottingham (UK)

ROR

<https://ror.org/01ee9ar58>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research (NIHR) (UK) - Research for Patient Benefit (RfPB) Programme

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2014		Yes	No
HRA research summary			28/06/2023	No	No